

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)

June 28, 2023

QUESTIONS

1. **DISCUSSION:** Discuss the evidence of effectiveness for palovarotene in study 301. In your discussion, consider the following:
 - a. The use of post hoc analyses to support a demonstration of efficacy
 - b. The interpretability of the results using the external control (Natural History Study)
2. **DISCUSSION:** Discuss your view of the flare-up events in subjects treated with the proposed palovarotene dosing regimen and the relevance to benefit-risk considerations. Also comment on whether you have concerns about other safety issues included in the meeting materials and slide presentations or discussed today.
3. **VOTE:** Does the evidence from Study 301 of palovarotene's treatment effect show the drug is effective in patients with fibrodysplasia ossificans progressiva (FOP)?
 - a. Provide the rationale for your vote.
4. **VOTE:** Do the benefits of palovarotene outweigh its risks for the treatment of patients with FOP?
 - a. If you voted yes, provide the rationale for your vote.
 - b. If you voted no, provide the rationale for your vote, and provide recommendations for additional data that may support a conclusion that the benefits outweigh the risks.